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SUMMARY A great deal of pharmaceutical research is nowadays carried out in developing countries such as Pakistan. Is it, however, beneficial for the country and the participants, often the poorly
educated and illiterate? Pharmaceutical research in Pakistan can bring benefits to both patients and
country. Promotion of good clinical practice and the development of national guidelines are advocated.
Government and industry both have a role to play to maintain the right balance.
Recherche pharmaceutique : paradoxe, défi ou dilemme ?
RÉSUMÉ Une grande partie de la recherche pharmaceutique est réalisée de nos jours dans des pays
en développement tels que le Pakistan. Cependant, le pays et les participants, qui souvent sont les
personnes ayant peu d’instruction et illettrées, en tirent-ils un quelconque bénéfice ? La recherche
pharmaceutique au Pakistan peut procurer des avantages aux patients ainsi qu’au pays. La promotion
des bonnes pratiques cliniques et l’élaboration de lignes directrices nationales sont préconisées. Le
gouvernement et l’industrie ont tous deux un rôle à jouer pour maintenir le juste équilibre.
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Introduction
Globalization of health research and the
conduct of clinical trials involving human
participants over the past few decades has
highlighted a number of ethical issues,
especially in those situations in which organizations sponsoring research carry out
studies in other countries. These may be
done as a way of helping the host country
address a public health problem; the research sponsor may consider the foreign
location more convenient, more efficient,
or less troublesome for a specific study; or
the study may be carried out as a joint effort
to address a specific health concern that is
important in both countries.
The pace and scope of international
collaboration in biomedical research have
increased during the past few years, and
now questions about the ethics of designing,
conducting, and following up clinical trials
have re-emerged. There is concern that
research done by scientists from the richer
countries but carried out in poorer nations
that are heavily burdened by disease may
be seen as imposing ethically inappropriate burdens on the host country and on
the participants themselves. The potential
for exploitation has engendered efforts to
ensure that those who participate in international clinical trials are protected.
Pakistan is one of the developing countries where balance still needs to be attained
between supply and demand in health care.
Health care spending is escalating at a rate
of US$ 0.3 billion per annum, which translates in to US$ 100 million per annum rise
in pharmaceutical sales [1]. Unfortunately,
the number of physicians per 1000 population remains static [1]. This is an indicator
of the enormous burden of health care expenditure on the Indian subcontinent, where
per capita annual income is equivalent to
about $US 400. The public health system
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receives 0.8%–4.0% of the gross national
product [2] (compared with 10%–15% in
developed countries [3]). These hard facts,
coupled with the general lack of third-party
health insurance, mean that < 40% of our
population has access to pharmaceuticals
[1].
The major portion of our population,
therefore, relies on alternative medicine,
primarily practised by sidewalk practitioners, e.g. people practising the homeopathic
system or unani tibb (Greek medicine);
herbal or traditional healers; and spiritual
healers (pirs, aamils, etc).

The pharmaceutical industry
and research
The market in Pakistan
The role of the pharmaceutical industry
needs to be explored. The Pakistani pharmaceutical market is estimated to be US $1.25
billion. There are 35 000 pharmaceuticals
registered in the country [4]; prepackaged
and formulated preparations are the mainstay of the industry. The usage, distribution,
dispensing and administration monitoring
aspects go unchecked, and the primary focus
remains on production. The main share of
the market is enjoyed by antibiotics (28%),
followed by gastrointestinal drugs (14%)
and respiratory medications (8%) .
The market shares of multinational and
indigenous companies are converging quite
rapidly. It could be depicted as an approximate 5% loss in local market share annually
for the multinational companies, which are
rapidly being overtaken by the local pharmaceutical companies. An analysis of the
7-year period 1998–2005 clearly shows a
shift of market share from 30:70 to 50:50
for local and multinational companies. The
annual growth rate for the Pakistani pharmaceutical market is estimated to be 5%,
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with a 10% rise in institutional sales. This
has a far-reaching impact on the research
that is conducted in the country, and also
on the quality of pharmaceuticals in clinical
research.
Challenge: research and
development
Most of the developing countries lack active
research and development laboratories. The
majority of industrial processing revolves
around packaging and formulation. This, of
course, leaves the pharmaceutical companies, primarily the multinational companies
but some local ones too, at an advantage
and allows them to proliferate in this area:
research and development remains solely
their realm. The research and development
of a drug needs 3–4 times more capital
today compared to 10–15 years ago. The
graphical representation of the research and
development expenditure of developed nations, particularly Japan, the United States
of America and the European countries,
provides a fair idea about this rise. Between
1990 and 2004, expenditure on drug research and development in Europe rose from
7941 to 21 500 million euros. In the United
States of America during the same period, it
rose from 6015 to 27 095 million euros, and
in Japan from 1990 to 2003 expenditure rose
from 3941 to 6743 million euros.”
While analysing the data, it should be
remembered that marketing expenditures
are always embedded with research and
development activities. A breakdown of
research and development activities of 9
top pharmaceutical companies shows that
30% of expenditure is used for discovery
research and 35% for clinical evaluation;
22 % is accounted for by non-clinical evaluation [5]. This 22% of the expenditure could
be linked to marketing investment.

Additionally, when comparing the pharmaceutical industry with other industries,
the research and development expenditure
is proclaimed to be much higher [5]. This
could be a result of the large marketing
expenses component, which is obviously
not an element of core research.
Paradox
The number of trials conducted in the developing countries is lamentable: 90% of medical research funds are spent on the richest,
i.e. 10% of the world’s population [6], and
research and development expenditure for
diseases of poverty (e.g. malaria, tropical
diseases, tuberculosis etc.) is regarded as
high risk (failure) and providing low returns. Drug trials in developing countries
are usually initiated outside the country
and dominated by the partner from the developed country, for example, PharmaciaUpjohn has a research and development
budget of US$ 2.2 billion per year, but only
6% is spent in Asia, mainly in Singapore,
Taiwan, Hong Kong and Korea [7]. In his
1999 article, Silverstein says, “Many people of the Third World die of preventable,
curable diseases. … malaria, tuberculosis,
acute lower-respiratory infections claiming 6.1 million lives in 1998. People die
because the drugs to treat those illnesses
are nonexistent or are no longer effective,
and they die because it doesn’t pay to keep
them alive” [7].
This unequal equation of overlooking
diseases of the poor can be well illustrated
when one identifies the origin of research
money: in the United States of America,
70% of research is funded by industry and
only 30% by the National Institute of Health
[8]. It would be interesting to know the
fringe benefits involved in the sponsored
trials fuelled by the research and develop-
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ment expenditure. The following rates will
definitely serve as an eye opener [9–11]:
• paid speaking arrangements: ranging
from $250 to $20 000/year;
• paid consultancies: mostly less than
$10 000 but may be up to $120 000/
year;
• paid positions on advisory boards, equity holdings: mostly over $10 000 and
ranging up to $1 million/year.
Apart from these overwhelming incentives, the “luncheons” should not be left
unaddressed. Across the United States of
America, as a part of their research efforts,
drug companies sponsor close to 300 000
events for doctors every year, many of them
far more generous than a free pizza [10].
Dilemma
Millions of people die from preventable or
curable diseases every week. But there is
no market in the sense that, unlike Viagra,
medicines for leishmaniasis are needed by
poor people in poor countries. Pharmaceutical companies judge that they would not get
sufficient return on research investment, so
why, they ask, should they bother? Their obligation to shareholders, they say, demands
that they put their effort into trying to find
cures for the diseases of affluence and longevity: heart disease, cancer, Alzheimer’s.
Of the thousands of new compounds drugs
companies have brought onto the market
in recent years, less than 1% have been for
tropical diseases [12].
Pharmaceutical companies may not be
altruistic, but they may still have a powerful
reason for sticking to ethical practices: “It’s
not in anyone’s interest to do anything that
would ultimately result in a drug being recalled,” said Kate Robins, a spokeswoman
for Pfizer. “You wouldn’t spend a billion
dollars if you’re going to cut corners and
it’s going to ultimately be recalled. You’re
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going to go into places where you can hold
up to standards that are international,” she
said [13]. “There is no easier, softer way.
There just isn’t.”

Drug trials in developing
countries
Another area of concern regarding clinical
trials is the vertical transmission trials conducted in a variety of developing countries
by researchers from more-developed countries. These illustrate a variety of ethical
issues. Three crucial issues are the injustice
of the use of placebo control groups, the
coercion used to recruit participants, and
the exploitation of developing countries. A
2002 study examined each of these issues
separately. It developed a new standard for
when placebo control groups are acceptable
and concluded that the issue of coercive offers was not well founded. and that concerns
about exploitation are better addressed by
assurances about the future care of the participants in the trial than by assurances of
availability of the drugs in the country in
general [14].
Against this background, it is hard to tie
in ethics with research. Essentially, research
requires expertise, diligence, honesty and
integrity. Ethical research is vital to generate sound knowledge, but what does the
ethical conduct of research involve? The
concern regarding ethical consideration in
research in developing countries could be
expressed by the following questions. How
does one obtain informed consent from
people who cannot read and write? Who
oversees the trials in areas where ethical
review committees are unknown? Is the disease under investigation similar in different
countries (epidemiological data are required
to answer this question)? Is the trial relevant
to the country? Are the risk factors the
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same, is the treatment relevant and are the
outcomes approximately the same? Do the
culture and infrastructure exist to carry out
this trial [15]?
The researcher may wish to stratify a
method for obtaining genuine consent for
participation, keeping in mind the standard
of care locally and in developed countries.
There is always an abundance of vulnerable communities in developing countries,
and this is so in Pakistan. Limited economic
development; inadequate community/cultural experience with, or understanding
of, scientific research; limited availability
of health care and treatment options; and
limited ability of individuals in the community to provide informed consent are some
factors requiring much attention. In many
countries, it is important for researchers to
obtain permission from local leaders before
seeking individual informed consent, and
to discuss other aspects of the research.
Although it may be difficult to identify the
members of the community who should be
consulted and to determine the level of authority they should have to permit researchers to approach potential participants, we
believe that such consultations can be helpful in improving both the informed consent
process and the overall research design.

Good clinical practice
What is the importance of good clinical
practice? Ideally speaking, it protects the
right of study subjects with respect to integrity and confidentiality. Good clinical practice also ensures that the data-driven results
are credible. Scientifically, clinical trials
are carried out for the testing of hypotheses,
registering new drugs and devices, postmarketing surveillance in order to document efficacy and safety, and to obtain data
for publication. Hence, the methodology of
the clinical trial matters a lot. Study design,

selection of appropriate subjects, adequate
sample size, duration of the study and effectiveness of follow-up are some important
aspects that may reflect on the credibility of
the results.
Good clinical practice remains essential
no matter where the study is conducted or
who is conducting it. The prime concern is
why developing countries are the favoured
location for clinical trials. The large patient
population, low incurred costs, a legislative
vacuum or shortcomings, ignorance about
legal and ethical issues and a strong desire
among the developing countries to link up
with institutions from rich countries at any
cost could be the most likely reasons.
The developing countries do need clinical
trials to be conducted—for the development
of new medicines and regimens suitable
for the local environment; to verify safety
and efficacy on different ethnic groups; for
academic interest and stimulation; and to
generate income for institutions as well as
individual financial reward. These are important considerations as far as developing
countries are concerned.
Good clinical practice in Pakistan
In Pakistan, the government has definitely
recognized the graveness of the issue, reacting to it by forming in 2002/03 a Ministry
of Health/World Health Organization committee on good clinical practice, functioning
as a Ministry of Health Research Cell. The
final draft of the Pakistan good clinical
practices has been sent to the World Health
Organization for review.
On the part of our pharmaceutical industry, some issues still need to be resolved:
lack of infrastructure and the overwhelming
contribution of multinational industries in
trials disturbs the equilibrium.
The way trials in Pakistan are conducted
is deplorable. They are mostly phase IV
(replicate) trials, which are more promo-
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tional than evaluative. Company-sponsored
clinical drug trials mostly use drugs supplied as samples. The majority of them are
non-randomized, uncontrolled and open
label. They are disguised as post-marketing
surveillance, but in reality their anticipated
outcome is to broaden the market share. The
pharmaceutical companies have taken over
the greater proportion of trials conducted;
investigator-initiated trials and independent
international publications are rare entities.
As has already been mentioned, local
institutions in developing countries, particularly Pakistan, have an interest in tagging
along on trials run by the multinationals;
it is, however, worth noting the situation
of our citizens participating in the clinical
trials.
Access to healthcare facilities and pharmaceuticals is still a dream for most of the
population. The lack of third-party insurance and governmental healthcare coverage
policies may encourage people to participate in clinical trials as this may the only
way they can obtain medical attention and
get a chance to gain access to healthcare facilities. These poorly educated, and mostly
illiterate, persons do not understand the
consequences of being research subjects.
Role of the ethical review committee
In such a scenario, where a person is not
aware of his or her rights and safety once
inducted into the study, the ethical review
committee needs to play a strong role in the
interests of the population. The dilemma is
that the ethical review committee in a developing country may overlook the importance of the local value system and also the
adequacy of resources. The committee may
fail to acquire the representation of social
scientists, ethicists and other allied health
professionals; thus, ethical review committees remain mostly physician-driven. Problems which initially appear minor, such as
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inadequate translation of informed consent
in national languages, may turn out to be a
nightmare for the study participants.
Involvement of clinicians
Clinicians have a complex relationship with
the pharmaceutical industry, and need to
critically evaluate their handling of samples and their contact with pharmaceutical
company representatives to optimize this
relationship and ensure quality patient care.
Clinics with specific policies for interactions with drug companies appear to derive
greater satisfaction from their encounters.
Gifts, no matter how small, produce a
sense of reciprocity in the recipient; this
is why pharmaceutical companies provide
pens, notepads, name badge holders, etc.
Social science has documented the way that
gift recipients feel impelled to do something
in return for the giver. However, this creates
a conflict of interests: the desire to cure
the patient versus the subconscious need
to repay the drug company’s generosity.
While these 2 goals can be congruent, they
may not be.
Entitlement is also an issue: students
and resident physicians feel entitled to a
good lunch and cool gadgets from the drug
companies.
Role of the authorities
On the part of the regulatory authorities,
a revolutionary transformation is required
to provide the infrastructure to support research, ensure standards of care and safety,
develop guidelines/legislation and implement standards. The Government of Pakistan has taken the initiative to formalize
a National Committee on Good Clinical
Practice and Good Prescribing Practice. The
committee is to be a guideline-formulating
body and will be responsible for training
the health care community by organizing
courses and seminars.
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Conclusion
Promotion of good clinical practice in countries such as Pakistan requires mass awareness and education campaigns, training
programmes or course development, the
development of national guidelines, government and health ministry involvement at
all levels and regular monitoring to evaluate
benefits and ensure progress.
Pharmaceutical research is crucial to
Pakistan. It brings benefit to the patients
and wealth to the country. Government and
industry have a definite role to play to keep
the right balance between industrial policy
and health policy. One should welcome and
reward innovation, regulate less and better.
The unprecedented movement between

countries of people, goods and ideas has
increased awareness of the imbalance in the
global burden of disease among the citizens
of developed countries. This is sometimes
referred to as the 10/90 gap: less than 10%
of global health care expenditure is devoted
to conditions that account for 90% of the
global burden of disease [16].
Initiatives to reduce the burden of disease in developing countries are urgently
needed. Clinical trials responsive to the
health care needs of developing countries
are one such initiative. It is, however, neither necessary nor desirable to lower ethical
standards in order to achieve this goal. On
the contrary, standards should be maintained, and adapted specifically to the needs
of developing countries.
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e-Health Code of Ethics
On Wednesday, May 24, 2000 the e-Health Ethics Initiative introduced
a code of ethics for health care sites and services on the Internet. The
“e-Health Code of Ethics” will help people worldwide realize the potential of the Internet for improving health and minimize its potential for
doing harm. The e-Health Code is available in Arabic, Chinese, English,
French, German and Spanish at: http://www.ihealthcoalition.org/. The
Arabic version is also available on the EMRO website at: http://www.
emro.who.int/his/medicalethics.htm
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